Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Tsiurikhis Sameditsino … | Healthcare Services | 7.2% | 41st pct | 268 |
| Sena-Medi | Healthcare Services | 0.4% | 24th pct | 268 |
| LJ Da Company - Dasavle… | Healthcare Services | -6.7% | 17th pct | 268 |
| Academician N. Kipshidz… | Healthcare Services | -198.5% | 1st pct | 268 |
| Mardaleishvili Medical … | Healthcare Services | — | no FY data | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 4 of 5 peers filed FY2024. Switch to FY2022 (5 of 5).
| Ratio — FY 2024 | Sena-Medi | Tsiurikhis Sameditsino … | Academician N. Kipshidz… | LJ Da Company - Dasavle… | Mardaleishvili Medical … |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 51.0% | 45.9% | 66.4% | 10.5% | — |
| EBITDA Margin | 0.4% | 7.2% | -198.5% | -6.7% | — |
| EBITDAR | 99 | 412 | -7,078 | -217 | — |
| EBITDAR Margin | 2.6% | 11.4% | -198.5% | -6.7% | — |
| EBIT Margin | -6.8% | 3.1% | -272.8% | -15.8% | — |
| Net Profit Margin | -12.2% | 2.9% | 82.8% | -21.1% | — |
| Operating Expense % of Sales | 50.6% | 38.7% | 264.9% | 17.2% | — |
| Returns | |||||
| Return on Assets (ROA) | -9.6% | 6.2% | 10.6% | -14.2% | — |
| Return on Equity (ROE) | -35.7% | 15.1% | 20.2% | N/A | — |
| ROIC [EBIT / Invested Capital] | |||||
| -8.3% |
| 17.1% |
| -73.6% |
| -107.9% |
| — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 39.1% | 0.6% | 2.8% | 15.8% | — |
| Debt-to-Equity | 1.45x | 0.01x | 0.05x | -3.71x | — |
| Debt-to-EBITDA | 123.42x | 0.04x | N/A | N/A | — |
| Equity-to-Assets | 27.0% | 41.2% | 52.4% | -4.3% | — |
| Net Debt | 1,825 | -26 | -1,401 | 682 | — |
| Cash & Equivalents | 81 | 37 | 2,192 | 81 | — |
| Total Debt | 1,906 | 10 | 791 | 763 | — |
| Liquidity & working capital | |||||
| Current Ratio | 1.68x | 0.87x | 0.66x | 0.31x | — |
| Quick Ratio | 1.68x | 0.87x | 0.20x | 0.31x | — |
| Cash Ratio | 0.10x | 0.04x | 0.17x | 0.02x | — |
| Total Current Assets | 1,399 | 844 | 8,751 | 1,549 | — |
| Total Current Liabilities | 834 | 975 | 13,278 | 5,023 | — |
| Inventory | N/A | N/A | 6,037 | N/A | — |
| Trade Receivables | 1,316 | 471 | 522 | 832 | — |
| Trade Payables | 833 | 958 | 11,972 | 534 | — |
| Net Working Capital | 565 | -131 | -4,527 | -3,474 | — |
| Net Working Capital % of Revenue | 14.6% | -3.6% | -127.0% | -106.7% | — |
| Trade Working Capital | 483 | -487 | -5,413 | 298 | — |
| Trade Working Capital % of Revenue | 12.5% | -13.5% | -151.8% | 9.2% | — |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | 0.20x | N/A | — |
| Days Inventory Outstanding (DIO) | N/A | N/A | 1839.3 | N/A | — |
| Receivables Turnover | 2.94x | 7.65x | 6.83x | 3.91x | — |
| Days Sales Outstanding (DSO) | 124.3 | 47.7 | 53.4 | 93.3 | — |
| Payables Turnover | 2.27x | 2.03x | 0.10x | 5.46x | — |
| Days Payable Outstanding (DPO) | 160.6 | 179.4 | 3647.6 | 66.9 | — |
| Cash Conversion Cycle | -36.3 days | -131.7 days | -1754.8 days | 26.4 days | — |
| Asset Turnover | 0.79x | 2.17x | 0.13x | 0.68x | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | -242 | 554 | -11,330 | N/A | — |
| Free Cash Flow (OCF − Capex proxy) | -430 | 6 | -10,488 | N/A | — |
| Cash Conversion (OCF / EBITDA) | -1565.3% | 212.4% | N/A | N/A | — |
| Dividends Declared | N/A | N/A | 0 | N/A | — |
| Dividend Payout Ratio | N/A | N/A | 0.0% | N/A | — |